APA (7th ed.) Citation

IB, R., AL, M., & RG, B. (2020). In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding. Annals of internal medicine, 173(4), JC21. https://doi.org/10.7326/ACPJ202008180-021

Chicago Style (17th ed.) Citation

IB, Riaz, Marshall AL, and Badgett RG. "In Cancer-associated VTE, Apixaban Was Noninferior to Dalteparin for Recurrence and Did Not Increase Major Bleeding." Annals of Internal Medicine 173, no. 4 (2020): JC21. https://doi.org/10.7326/ACPJ202008180-021.

MLA (9th ed.) Citation

IB, Riaz, et al. "In Cancer-associated VTE, Apixaban Was Noninferior to Dalteparin for Recurrence and Did Not Increase Major Bleeding." Annals of Internal Medicine, vol. 173, no. 4, 2020, p. JC21, https://doi.org/10.7326/ACPJ202008180-021.